Andere Sprachen Molecular Partners AG Nasdaq

Aktien

A3CSB5

US60853G1067

MOLN

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 03.05.2024			% 5 Tage	% 1. Jan.
3,98 ^USD	+5,71 %		+2,58 %	-4,78 %

30.04.	Morning Briefing - Markt Schweiz	AW
29.04.	Molecular Partners mit positivem Expertenbericht zum Leukämie-Kandidat MP0533	AW

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action	29.04.
Molecular Partners AG Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action	29.04.
Molecular Partners : Annual General Meeting Minutes	26.04.
Life Science Cares Launches in Switzerland	19.04.
Molecular Partners : statement regarding Passive Foreign Investment Company status	18.04.
Principales informations avant-Bourse	18.04.
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting	17.04.
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting	17.04.
Principales informations avant-Bourse	08.04.
Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	01.04.
Molecular Partners Publishes Invitation to Annual General Meeting 2024	26.03.
Molecular Partners Publishes Invitation to Annual General Meeting 2024	26.03.
Principales informations avant-Bourse	15.03.
Molecular Partners Swings to Loss in FY23; Revenue Down	15.03.
Molecular Partners financé jusque loin en 2026	14.03.
Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023	14.03.
Molecular Partners AG Reports Earnings Results for the Full Year Ended December 31, 2023	14.03.
Principales informations avant-Bourse	14.03.
US Court Dismisses Putative Class Action Against Molecular Partners	04.03.
Molecular Partners: procédure collective classée aux USA	01.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Molecular Partners AG Nasdaq

Aktien

A3CSB5

US60853G1067

MOLN

Andere Sprachen

Filter